禾蔻安 CISENDO®
全球首个无创子宫内膜癌筛查，填补临床空白
CDO1/CELF4 双基因甲基化，无创采样替代有创活检，全球首个无创内膜癌筛查，填补临床空白。
扎实的临床数据支撑
基于多中心注册临床试验，灵敏度与特异性均达到行业领先水平。
谁需要这项检测？
- 异常子宫出血女性
- 绝经后女性子宫内膜癌筛查
- 围绝经期女性内膜病变风险评估
- 拟行宫腔镜检查的高风险女性
临床如何应用？
- 子宫内膜癌无创早筛
- 宫腔镜术前风险分层，减少不必要的有创检查
- 高危人群的随访与监测
- 体检中心女性健康筛查方案
为什么选择我们
全球首个无创子宫内膜癌甲基化检测产品
全球专利、CE 认证、马来西亚注册证
获《子宫内膜癌三级预防策略中国专家共识》推荐
获《子宫内膜癌基因甲基化筛查技术临床应用专家共识》推荐
子宫内膜癌 相关学术文献
CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts
期刊：Gynecologic Oncology
发表单位：Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University)
DOI: 10.1016/j.ygyno.2026.01.776
DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
期刊：International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society
发表单位：the Third Xiangya Hospital, Central South University
DOI: 10.1136/ijgc-2024-005723
CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts
期刊：Gynecologic Oncology
发表单位：Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University)
DOI: 10.1016/j.ygyno.2026.01.776
DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
期刊：International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society
发表单位：the Third Xiangya Hospital, Central South University
DOI: 10.1136/ijgc-2024-005723
